Welcome to LookChem.com Sign In|Join Free

CAS

  • or
9-Bromononanoic acid is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals and chemicals. It is characterized by its bromine atom attached to a nonanoic acid chain, which contributes to its unique chemical properties and reactivity.

41059-02-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 41059-02-3 Structure
  • Basic information

    1. Product Name: 9-Bromononanoic acid
    2. Synonyms: 9-BROMONONANOIC ACID;9-Bromononanoic acid, tech;9-BROMO-N-NONANOIC ACID;Nonanoic acid, 9-bromo-
    3. CAS NO:41059-02-3
    4. Molecular Formula: C9H17BrO2
    5. Molecular Weight: 237.13
    6. EINECS: N/A
    7. Product Categories: Organic acids;omega-Bromocarboxylic Acids;omega-Functional Alkanols, Carboxylic Acids, Amines & Halides
    8. Mol File: 41059-02-3.mol
    9. Article Data: 22
  • Chemical Properties

    1. Melting Point: 39°C
    2. Boiling Point: 165°C/3mm
    3. Flash Point: 145.8 °C
    4. Appearance: /
    5. Density: 1.282 g/cm3
    6. Vapor Pressure: 8.17E-05mmHg at 25°C
    7. Refractive Index: 1.485
    8. Storage Temp.: Refrigerator
    9. Solubility: Chloroform (Soluble), DMSO (Slightly)
    10. PKA: 4.78±0.10(Predicted)
    11. CAS DataBase Reference: 9-Bromononanoic acid(CAS DataBase Reference)
    12. NIST Chemistry Reference: 9-Bromononanoic acid(41059-02-3)
    13. EPA Substance Registry System: 9-Bromononanoic acid(41059-02-3)
  • Safety Data

    1. Hazard Codes: Xi
    2. Statements: 34
    3. Safety Statements: 36/37/39
    4. RIDADR: 3261
    5. WGK Germany:
    6. RTECS:
    7. HazardClass: IRRITANT
    8. PackingGroup: III
    9. Hazardous Substances Data: 41059-02-3(Hazardous Substances Data)

41059-02-3 Usage

Uses

Used in Pharmaceutical Synthesis:
9-Bromononanoic acid is used as an intermediate in the synthesis of Rumenic Acid (R701590), a trans fatty acid with potential health benefits. It is believed to reduce the risk of cancer and cardiovascular diseases, as well as prevent disease processes that lead to chronic inflammation, atherosclerosis, and diabetes.
Used in Chemical Synthesis:
9-Bromononanoic acid is also utilized in the chemical industry as a building block for the creation of various compounds with specific applications. Its bromine atom and nonanoic acid chain make it a versatile starting material for the development of new products with tailored properties.

Check Digit Verification of cas no

The CAS Registry Mumber 41059-02-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,1,0,5 and 9 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 41059-02:
(7*4)+(6*1)+(5*0)+(4*5)+(3*9)+(2*0)+(1*2)=83
83 % 10 = 3
So 41059-02-3 is a valid CAS Registry Number.
InChI:InChI=1/C9H17BrO2/c10-8-6-4-2-1-3-5-7-9(11)12/h1-8H2,(H,11,12)

41059-02-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 9-Bromononanoic acid

1.2 Other means of identification

Product number -
Other names Nonanoic acid,9-bromo

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:41059-02-3 SDS

41059-02-3Relevant articles and documents

Syntheses and physical properties of ferrocene derivatives (XIII)

Nakamura,Setodoi,Hanasaki

, p. 93 - 101 (2000)

Two monosubstituted ferrocene derivatives, 8-[4-(4-methoxyphenoxycarbonyl)phenoxycarbonyl]octyl 4-ferrocenylbenzoate (MPAF-8) and 9-[4-(4-methoxyphenoxycarbonyl)phenoxycarbonyl] nonyl 4-ferrocenylbenzoate (MPAF-9), were synthesized and their phase transition behavior was studied using a differential scanning calorimeter, a polarizing microscope and an X-ray diffractometer. MPAF-8 exhibited two liquid crystalline phases in both heating and cooling processes at approximately room temperature. In the heating process, a crystal-crystal phase transition behavior was ascertained. The phase transition behavior of MPAF-9 was very similar to that of MPAF-8 except for the behavior of the crystal-crystal phase transition in the heating process. In MPAF-8, one crystalline phase was transformed into another crystalline phase completely. On the other hand, this transformation was observed in part in MPAF-9, and as a result, the melting behavior was observed two times in the heating process.

Chemoproteomic profiling reveals cellular targets of nitro-fatty acids

Chen, Yi-Ting,Fang, Ming-Yu,Hsiao, Wan-Chi,Huang, Kuan-Hsun,Ke, Yi-Yu,Pan, Pei-Yun,Tsou, Lun K.,Tu, Wei-Ju,Zhang, Mingzi M.

, (2021/09/14)

Nitro-fatty acids are a class of endogenous electrophilic lipid mediators with anti-inflammatory and cytoprotective effects in a wide range of inflammatory and fibrotic disease models. While these beneficial biological effects of nitro-fatty acids are mainly attributed to their ability to form covalent adducts with proteins, only a small number of proteins are known to be nitro-alkylated and the scope of protein nitro-alkylation remains undetermined. Here we describe the synthesis and application of a clickable nitro-fatty acid probe for the detection and first global identification of mammalian proteins that are susceptible to nitro-alkylation. 184 high confidence nitro-alkylated proteins were identified in THP1 macrophages, majority of which are novel targets of nitro-fatty acids, including extended synaptotagmin 2 (ESYT2), signal transducer and activator of transcription 3 (STAT3), toll-like receptor 2 (TLR2), retinoid X receptor alpha (RXRα) and glucocorticoid receptor (NR3C1). In particular, we showed that 9-nitro-oleate covalently modified and inhibited dexamethasone binding to NR3C1. Bioinformatic analyses revealed that nitro-alkylated proteins are highly enriched in endoplasmic reticulum and transmembrane proteins, and are overrepresented in lipid metabolism and transport pathways. This study significantly expands the scope of protein substrates targeted by nitro-fatty acids in living cells and provides a useful resource towards understanding the pleiotropic biological roles of nitro-fatty acids as signaling molecules or as multi-target therapeutic agents.

A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration

González-Gil, Inés,Zian, Debora,Vázquez-Villa, Henar,Hernández-Torres, Gloria,Martínez, R. Fernando,Khiar-Fernández, Nora,Rivera, Richard,Kihara, Yasuyuki,Devesa, Isabel,Mathivanan, Sakthikumar,Del Valle, Cristina Rosell,Zambrana-Infantes, Emma,Puigdomenech, María,Cincilla, Giovanni,Sanchez-Martinez, Melchor,Rodríguez De Fonseca, Fernando,Ferrer-Montiel, Antonio V.,Chun, Jerold,López-Vales, Rubén,López-Rodríguez, María L.,Ortega-Gutiérrez, Silvia

supporting information, p. 2372 - 2390 (2020/01/02)

Neuropathic pain (NP) is a complex chronic pain state with a prevalence of almost 10% in the general population. Pharmacological options for NP are limited and weakly effective, so there is a need to develop more efficacious NP attenuating drugs. Activation of the type 1 lysophosphatidic acid (LPA1) receptor is a crucial factor in the initiation of NP. Hence, it is conceivable that a functional antagonism strategy could lead to NP mitigation. Here we describe a new series of LPA1 agonists among which derivative (S)-17 (UCM-05194) stands out as the most potent and selective LPA1 receptor agonist described so far (Emax = 118%, EC50 = 0.24 μM, KD = 19.6 nM; inactive at autotaxin and LPA2-6 receptors). This compound induces characteristic LPA1-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of NP.

Tandem IBX-Promoted Primary Alcohol Oxidation/Opening of Intermediate β,γ-Diolcarbonate Aldehydes to (E)-γ-Hydroxy-α,β-enals

Kumari, Anupama,Gholap, Sachin P.,Fernandes, Rodney A.

, p. 2278 - 2290 (2019/06/17)

A tandem IBX-promoted oxidation of primary alcohol to aldehyde and opening of intermediate β,γ-diolcarbonate aldehyde to (E)-γ-hydroxy-α,β-enal has been developed. Remarkably, the carbonate opening delivered exclusively (E)-olefin and no over-oxidation of γ-hydroxy was observed. The method developed has been extended to complete the stereoselective total synthesis of both (S)- and (R)-coriolides and d-xylo- and d-arabino-C-20 guggultetrols.

Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors

Shibuya, Kimiyuki,Kawamine, Katsumi,Miura, Toru,Ozaki, Chiyoka,Edano, Toshiyuki,Mizuno, Ken,Yoshinaka, Yasunobu,Tsunenari, Yoshihiko

, p. 4001 - 4013 (2018/06/26)

We describe our molecular design of aortic-selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT, also abbreviated as SOAT) inhibitors, their structure–activity relationships (SARs) and their pharmacokinetic (PK) and pharmacological profiles. The connection of two weak ligands—N-(2,6-diisopropylphenyl)acetamide (50% inhibitory concentration [IC50] = 8.6 μM) and 2-(methylthio)benzo[d]oxazole (IC50 = 31 μM)—via a linker comprising a 6 methylene group chains yielded a highly potent molecule, 9-(benzo[d]oxazol-2-ylthio)-N-(2,6-diisopropylphenyl)nonanamide (3h) that exhibited high potency (IC50 = 0.004 μM) toward aortic ACAT. This head-to-tail design made it possible to markedly enhance the activity to 2150- to 7750-fold and to discriminate the isoform-selectivity based on the double-induced fit mechanism. At doses of 1 and 3 mg/kg, 3h significantly decreased the lipid-accumulation areas in the aortic arch to 74 and 69%, respectively without reducing the plasma total cholesterol level in high fat- and cholesterol-fed F1B hamsters. Here, we demonstrate the antiatherosclerotic effect of 3h in vivo via its direct action on aortic ACAT and its powerful modulator of cholesterol level. This molecule is a potential therapeutic agent for the treatment of diseases involving ACAT-1 overexpression.

Iron Catalysis for Room-Temperature Aerobic Oxidation of Alcohols to Carboxylic Acids

Jiang, Xingguo,Zhang, Jiasheng,Ma, Shengming

supporting information, p. 8344 - 8347 (2016/07/26)

Oxidation from alcohols to carboxylic acids, a class of essential chemicals in daily life, academic laboratories, and industry, is a fundamental reaction, usually using at least a stoichiometric amount of an expensive and toxic oxidant. Here, an efficient and practical sustainable oxidation technology of alcohols to carboxylic acids using pure O2 or even O2 in air as the oxidant has been developed: utilizing a catalytic amount each of Fe(NO3)3·9H2O/TEMPO/MCl, a series of carboxylic acids were obtained from alcohols (also aldehydes) in high yields at room temperature. A 55 g-scale reaction was demonstrated using air. As a synthetic application, the first total synthesis of a naturally occurring allene, i.e., phlomic acid, was accomplished.

DEOXYNOJIRIMYCIN DERIVATIVES AND METHODS OF THEIR USING

-

Paragraph 0021, (2016/08/29)

The present application provide novel iminosugars and their use in treatment of viral infections, such as Dengue infection and Influenza A infection. The present inventors discovered certain deoxynojirimycin derivatives may be effective against one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition caused by or associated with one or more viruses. In certain embodiments, the deoxynojirimycin derivatives may increase a survival rate or probability for a subject infected with one or more viruses, which may be, for example, a Dengue virus and/or a virus belonging to the Orthomyxoviridae family, such as an Influenza A virus.

QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE

-

Page/Page column 81, (2014/05/24)

The present invention relates to novel nitric oxide donor compounds for the use in the treatment and/or prophylaxis of hypertensive glaucoma, normotensive glaucoma and ocular hypertension.

Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites

Olaleye, Tayo O.,Brannigan, James A.,Roberts, Shirley M.,Leatherbarrow, Robin J.,Wilkinson, Anthony J.,Tate, Edward W.

supporting information, p. 8132 - 8137 (2015/01/08)

N-Myristoyltransferase (NMT) has been shown to be essential in Leishmania and subsequently validated as a drug target in Plasmodium. Herein, we discuss the use of antifungal NMT inhibitors as a basis for inhibitor development resulting in the first sub-micromolar peptidomimetic inhibitors of Plasmodium and Leishmania NMTs. High-resolution structures of these inhibitors with Plasmodium and Leishmania NMTs permit a comparative analysis of binding modes, and provide the first crystal structure evidence for a ternary NMT-Coenzyme A/myristoylated peptide product complex. This journal is

QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS

-

Page/Page column 86, (2013/05/21)

The present invention relates to nitric oxide donor compounds having a quinone based structure, to processes for their preparation and to their use in the treatment of pathological conditions where a deficit of NO plays an important role in their pathogenesis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 41059-02-3